Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026

Reuters2026/07/17 14:29

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immatics flagged three ESMO Congress 2026 presentations as key updates across its PRAME franchise spanning cell therapies and a bispecific program.
New Phase 1b data for lead PRAME cell therapy anzu-cel in metastatic cutaneous and uveal melanoma will focus on predictors of durable response.
Phase 1 results for IMA203CD8 across PRAME-positive solid tumors will include durability follow-up at clinically relevant dose levels in gynecologic cancers.
Phase 1b data for PRAME bispecific IMA402 at the recommended Phase 2 dose range across multiple cancers will support expansion and combination plans.
Abstracts are scheduled for release on Oct. 19, 2026; presentations run Oct. 23-24 during ESMO in Madrid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief on July 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026

You may also like

Crypto prices